HRP20000314A2 - Use of ketolides for preventing arterial thrombotic complications related to atherosclerosis - Google Patents
Use of ketolides for preventing arterial thrombotic complications related to atherosclerosis Download PDFInfo
- Publication number
- HRP20000314A2 HRP20000314A2 HR20000314A HRP20000314A HRP20000314A2 HR P20000314 A2 HRP20000314 A2 HR P20000314A2 HR 20000314 A HR20000314 A HR 20000314A HR P20000314 A HRP20000314 A HR P20000314A HR P20000314 A2 HRP20000314 A2 HR P20000314A2
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- dideoxy
- radical
- ketolide
- use according
- Prior art date
Links
- 239000003835 ketolide antibiotic agent Substances 0.000 title claims description 17
- 201000001320 Atherosclerosis Diseases 0.000 title claims description 6
- 230000001732 thrombotic effect Effects 0.000 title claims description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 17
- 229960003276 erythromycin Drugs 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 2
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 2
- -1 heteroaryl radical Chemical class 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 8
- 150000003254 radicals Chemical group 0.000 description 8
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 150000005840 aryl radicals Chemical class 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- RVHOBHMAPRVOLO-UHFFFAOYSA-N 2-ethylbutanedioic acid Chemical compound CCC(C(O)=O)CC(O)=O RVHOBHMAPRVOLO-UHFFFAOYSA-N 0.000 description 1
- YHVUVJYEERGYNU-UHFFFAOYSA-N 4',8-Di-Me ether-5,7,8-Trihydroxy-3-(4-hydroxybenzyl)-4-chromanone Natural products COC1(C)CC(O)OC(C)C1O YHVUVJYEERGYNU-UHFFFAOYSA-N 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- AJSDVNKVGFVAQU-BIIVOSGPSA-N cladinose Chemical group O=CC[C@@](C)(OC)[C@@H](O)[C@H](C)O AJSDVNKVGFVAQU-BIIVOSGPSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Description
Ovaj izum se odnosi na novu terapeutsku primjenu ketolida.
Izum se odnosi na upotrebu ketolida i njihove farmaceutski prihvatljive soli za dobivanje farmaceutskih pripravaka namijenjenih za preveniranje arterijskih trombotičkih komplikacija povezanih s aterosklerozom.
Termin “ketolid” se odnosi na derivate eritromicina kojima nedostaje kladinoza na položaju 3. Ti produkti imaju antibiotska svojstva (Antimicrobial Agents and Chemotherapy 1997, vol. 41, pp. 2149-2158, ili 1997 vol. 41, pp. 454 do 459, ili Lettre de l’infectiologue 1997, vol. 12, pp. 46 do 54).
Ketolidi su također opisani, na primjer, u Europskim patentima 0487411, 596802, 606024, 614905, 676409, 680967 i 799833 i Internacionalnoj patentnoj prijavi WO 98/25942.
Među poželjnim ketolidima iz izuma, mogu se spomenuti spojevi formule (I):
[image]
u kojoj R predstavlja radikal
(CH2)mOn(X)YAr
gdje m predstavlja broj 0 ili 1,
n predstavlja broj 0 ili 1,
X predstavlja radikal (NH)a, CH2 ili SO2, s time da a predstavlja broj 0 ili 1,
Y predstavlja radikal (CH2)b-(CH=CH)c-(CH2)d, s time da c = 0 ili 1 i b+c+d ≤ 8,
Z predstavlja vodik ili atom halogena,
Ar predstavlja opcionalno supstituirani aril ili heteroaril radikal.
Aril radikal može biti fenil ili naftil radikal.
Supstituirani ili nesupstituirani heterociklički radikal može biti tienil, furil, pirolil, tiazolil ili oksazolil radikal, imidazolil radikal, na primjer 4-(3-piridil)-1H-imidazolil radikal, tiadiazolil, pirazolil ili pirazinil radikal, ili alternativno indolil, benzofuril, benzotiazolil ili kinolil radikal.
Ovi aril radikali mogu sadržavati jednu ili više skupina odabranih iz skupine koju sačinjavaju hidroksil radikali, atomi halogena, NO2 radikali, CN radikali, alkil, alkenil ili alkinil radikali, O-alkil, O-alkenil ili O-alkinil radikali, S-alkil, S-alkenil ili S-alkinil radikali i N-alkil, N-alkenil ili N-alkinil radikali, koji sadržavaju do 12 ugljikovih atoma opcionalno supstituiranih s jednim ili više atoma halogena, radikal
[image] , gdje Ra i Rb, koji mogu biti identični ili različiti, predstavljaju vodikov atom ili alkil radikal koji sadržava do 12 ugljikovih atoma, radikal
[image] , gdje R3 predstavlja alkil radikal koji sadržava do 12 ugljikovih atoma, ili opcionalno supstituirani aril ili heteroaril radikal, gdje aril, O-aril ili S-aril karbociklički ili aril, O-aril ili S-aril heterociklički 5- ili 6-člani radikali sadržavaju jedan ili više heteroatoma, opcionalno supstituiranih s jednim ili više supstituenata spomenutih niže.
Poželjni heterocikli koji se mogu spomenuti su, među ostalim,
[image]
[image]
i heterociklički radikali predviđeni u Europskim patentnim prijavama 487411, 596802, 676409 i 680967. Ti poželjni heterociklički radikali mogu biti supstituirani jednom ili više funkcionalnih skupina.
Hal poželjno predstavlja atom fluora, klora ili broma.
Među adicijskim solima s kiselinama koje se mogu spomenuti su soli formirane s octenom kiselinom, propionskom kiselinom, trifluoroctenom kiselinom, hidroksisukcinskom kiselinom, vinskom kiselinom, metan-sulfonskom kiselinom, benzensulfonskom kiselinom, p-toluensulfonskom kiselinom i, naročito, stearinskom kiselinom, etilsukcinskom kiselinom ili laurilsulfonskom kiselinom.
Aril radikal je poželjno heterociklički aril radikal. Među poželjnim ketolidima koji se mogu spomenuti su spojevi u kojima Ar predstavlja radikal
[image]
Među poželjni spojevima izuma koji se mogu spomenuti su spojevi formule (I) čija imena su dana niže: 11,12-dideoksi-3-de[(2,6-dideoksi-3-C-metil-3-O-metil-alfa-L-riboheksopiranozil)oksi]-6-O-metil-3-okso-12,11-([oksikarbonil[[[2-[4-(3-piridil)-1H-imidazol-1-il]etoksi]-metil]imino]]eritromicin (spoj P) opisan u Patentnoj prijavi WO 98/25942 u Primjeru 2 ili 11,12-dideoksi-3-de((2,6-dideoksi-3-C-metil-3-O-metil-alfa-L-riboheksopiranozil)oksi)-6-O-metil-3-okso-12,11-(oksikarbonil((4-(3-(3-piridil)-1H-1,2,4-triazol-1-il)butil) imino)eritromicin (spoj P1) opisan u Patentu EP 680967 u Primjeru 35, ili 11,12-dideoksi-3-de((2,6-dideoksi-3-C-metil-3-O-metil-alfa-L-riboheksopiranozil)oksi)-2-fluoro-6-O-metil-3-okso-12,11-(oksikarbonil((4-(4-(3-piridil)-1H-imidazol-1-il)butil)imino))eritromicin (A izomer) (spoj P2) opisan u Patentu EP 799833 u Primjeru 3, ili 11,12-dideoksi-3-de((2,6-dideoksi-3-C-metil-3-O-metil-alfa-L-riboheksopiranozil)oksi)-6-O-metil-3-okso-12,11-(oksikarbonil((4-(4-(3-piridil)-1H-imidazol-1-il)butil)imino))eritromicin (spoj P3) opisan u Patentu EP 680967 u Primjeru 34.
Među ketolidima koji imaju naročitu prednost, mogu se spomenuti produkti iz Europskih patenata 676409, 680967 i 799833.
Ketolidi pokazuju anti-trombocit-agregacijsku i antitrombotičku aktivnost, kako su pokazali rezultati dobiveni u eksperimentalnom dijelu otkrivenom ispod.
Izum se dakle odnosi na farmaceutske pripravke namijenjene za preveniranje arterijskih komplikacija, kao što su cerebrovaskularni inzulti, infarkt miokarda i nestabilna angina nakon ateroskleroze.
Izgleda da infektivni uzročnik Clamydia pneumoniae ima ulogu u razvoju ateroskleroze kod čovjeka.
Ketolidi djeluju protiv Clamydiae pneumoniae.
Kao rezultat, anti-infektivna svojstva protiv Clamydiae pneumoniae, koja su povezan s njihovom anti-trombocit-agregacijskom aktivnošću omogućuju im da se upotrijebe za suzbijanje razvoja ateroskleroze i trombotičkih komplikacija.
Djelovanje produkta P na in vitro agregaciju trombocita - usporedba s aspirinom.
[image] + Trombociti zeca se stave u produkt u različitim koncentracijama i zatim se doda arahidonska kiselina u koncentraciji od 0,2 mM.
* n = 2 zeca ;* n = 4 zeca osim za koncentraciju 5 × 10-5 M, gdje n = 2.
Poželjni produkti P1, P2 i P3 spomenuti iznad također pokazuju dobro djelovanje u tom testu in vitro agregacije trombocita.
Claims (7)
1. Upotreba ketolida i njihovih farmaceutski prihvatljivih soli, naznačena time, što se upotrebljavaju za dobivanje farmaceutskih pripravaka namijenjenih za preveniranje arterijskih trombotičkih komplikacija povezanih s aterosklerozom.
2. Upotreba prema zahtjevu 1, naznačena time, što ketolid odgovara formuli (I):
[image]
u kojoj R predstavlja radikal
(CH2)mOn(X)YAr
gdje m predstavlja broj 0 ili 1,
n predstavlja broj 0 ili 1,
X predstavlja radikal (NH)a, CH2 ili SO2, s time da a predstavlja broj 0 ili 1,
Y predstavlja radikal (CH2)b-(CH=CH)c-(CH2)d, s time da c = 0 ili 1 i b+c+d ≤ 8,
Z predstavlja vodik ili atom halogena,
Ar predstavlja opcionalno supstituirani aril ili heteroaril radikal.
3. Upotreba prema zahtjevu 1 ili 2, naznačena time, što ketolid je 11,12-dideoksi-3-de[(2,6-dideoksi-3-C-metil-3-O-metil-alfa-L-riboheksopiranozil)oksi]-6-O-metil-3-okso-12,11-([oksikarbonil[[[2-[4-(3-piridil)-1H-imidazol-1-il]etoksi]-metil]imino]]eritromicin.
4. Upotreba prema bilo kojem od zahtjeva 1 do 3, naznačena time, što ketolid je 11,12-dideoksi-3-de((2,6-dideoksi-3-C-metil-3-O-metil-alfa-L-riboheksopiranozil)oksi)-6-O-metil-3-okso-12,11-(oksikarbonil((4-(3-(3-piridil)-1H-1,2,4-triazol-1-il)butil)imino)eritromicin.
5. Upotreba prema bilo kojem od zahtjeva 1 do 3, naznačena time, što ketolid je 11,12-dideoksi-3-de((2,6-dideoksi-3-C-metil-3-O-metil-alfa-L-riboheksopiranozil)oksi)-2-fluoro-6-O-metil-3-okso-12,11-(oksikarbonil((4-(4-(3-piridil)-1H-imidazol-1-il)butil)imino))eritromicin (A izomer).
6. Upotreba prema bilo kojem od zahtjeva 1 do 3, naznačena time, što ketolid je 11,12-dideoksi-3-de((2,6-dideoksi-3-C-metil-3-O-metil-alfa-L-riboheksopiranozil)oksi)-6-O-metil-3-okso-12,11-(oksikarbonil((4-(4-(3-piridil)-1H-imidazol-1-il)butil)imino))eritromicin.
7. Upotreba prema bilo kojem od zahtjeva 1 do 6, naznačena time, što ketolid se primjenjuje oralno u dozi između 50 i 600 mg dnevno.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9714358A FR2771008B1 (fr) | 1997-11-17 | 1997-11-17 | Utilisation des ketolides pour la preparation de compositions pharmaceutiques destinees a prevenir les complications thrombotiques arterielles liees a l'atherosclerose |
| PCT/FR1998/002436 WO1999025365A1 (fr) | 1997-11-17 | 1998-11-16 | Utilisation des ketolides pour prevenir les complications thrombotiques arterielles liees a l'atherosclerose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20000314A2 true HRP20000314A2 (en) | 2001-02-28 |
Family
ID=9513423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20000314A HRP20000314A2 (en) | 1997-11-17 | 2000-05-17 | Use of ketolides for preventing arterial thrombotic complications related to atherosclerosis |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US20080139489A1 (hr) |
| EP (1) | EP1030673B1 (hr) |
| JP (1) | JP4550273B2 (hr) |
| KR (1) | KR20010032130A (hr) |
| CN (1) | CN1286633A (hr) |
| AP (1) | AP1196A (hr) |
| AR (1) | AR014119A1 (hr) |
| AT (1) | ATE271875T1 (hr) |
| AU (1) | AU744419B2 (hr) |
| BG (1) | BG104427A (hr) |
| BR (1) | BR9814199A (hr) |
| CA (1) | CA2312021C (hr) |
| DE (1) | DE69825308T2 (hr) |
| DZ (1) | DZ2654A1 (hr) |
| EA (1) | EA003322B1 (hr) |
| EE (1) | EE04095B1 (hr) |
| ES (1) | ES2224446T3 (hr) |
| FR (1) | FR2771008B1 (hr) |
| GE (1) | GEP20032968B (hr) |
| HR (1) | HRP20000314A2 (hr) |
| HU (1) | HUP0004507A3 (hr) |
| ID (1) | ID24940A (hr) |
| IL (1) | IL136149A0 (hr) |
| MA (1) | MA26566A1 (hr) |
| NO (1) | NO20002435L (hr) |
| NZ (1) | NZ504305A (hr) |
| OA (1) | OA11411A (hr) |
| PL (1) | PL340373A1 (hr) |
| SK (1) | SK7042000A3 (hr) |
| TN (1) | TNSN98206A1 (hr) |
| TR (1) | TR200001384T2 (hr) |
| TW (1) | TW472061B (hr) |
| WO (1) | WO1999025365A1 (hr) |
| YU (1) | YU29600A (hr) |
| ZA (1) | ZA9810357B (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2777282B1 (fr) * | 1998-04-08 | 2001-04-20 | Hoechst Marion Roussel Inc | Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments |
| EP1137654A1 (en) * | 1998-12-10 | 2001-10-04 | Pfizer Products Inc. | Carbamate and carbazate ketolide antibiotics |
| EP1147121B1 (en) * | 1999-01-27 | 2003-12-17 | Pfizer Products Inc. | Ketolide antibiotics |
| EP1114826A3 (en) * | 1999-12-29 | 2001-10-31 | Pfizer Products Inc. | Novel antibacterial and prokinetic macrolides |
| JP2003529593A (ja) | 2000-04-04 | 2003-10-07 | スミスクライン ビーチャム パブリック リミテッド カンパニー | 抗菌剤として用いるための２−ヒドロキシムチリンカルバメート誘導体 |
| JP2004323414A (ja) * | 2003-04-24 | 2004-11-18 | Japan Science & Technology Agency | １４員環マクロライド化合物を利用した、血管平滑筋の増殖に起因する疾患治療剤 |
| GB0402578D0 (en) * | 2004-02-05 | 2004-03-10 | Cambridge Theranostics Ltd | Methods of treatment of atherosclerosis |
| JP6042334B2 (ja) * | 2010-09-10 | 2016-12-14 | センプラ ファーマシューティカルズ，インコーポレイテッド | 疾患治療のための水素結合形成フルオロケトライド |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5424187A (en) * | 1991-06-14 | 1995-06-13 | Board Of Regents Of The University Of Washington | Method of screening for arterial chlamydial granuloma |
| FR2718450B1 (fr) * | 1994-04-08 | 1997-01-10 | Roussel Uclaf | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. |
| FR2719587B1 (fr) * | 1994-05-03 | 1996-07-12 | Roussel Uclaf | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. |
| FR2742757B1 (fr) * | 1995-12-22 | 1998-01-30 | Roussel Uclaf | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments |
| US6271255B1 (en) * | 1996-07-05 | 2001-08-07 | Biotica Technology Limited | Erythromycins and process for their preparation |
| GB9621771D0 (en) * | 1996-10-18 | 1996-12-11 | St George S Enterprises Ltd | Method of treatment of heart disease |
| FR2757168B1 (fr) * | 1996-12-12 | 1999-06-11 | Hoechst Marion Roussel Inc | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments |
| EP0895999A1 (en) * | 1997-08-06 | 1999-02-10 | Pfizer Products Inc. | C-4" substituted macrolide antibiotics |
-
1997
- 1997-11-17 FR FR9714358A patent/FR2771008B1/fr not_active Expired - Fee Related
-
1998
- 1998-11-12 ZA ZA9810357A patent/ZA9810357B/xx unknown
- 1998-11-13 TW TW087118866A patent/TW472061B/zh not_active IP Right Cessation
- 1998-11-16 IL IL13614998A patent/IL136149A0/xx unknown
- 1998-11-16 EE EEP200000244A patent/EE04095B1/xx not_active IP Right Cessation
- 1998-11-16 ID IDW20000930A patent/ID24940A/id unknown
- 1998-11-16 AT AT98955662T patent/ATE271875T1/de not_active IP Right Cessation
- 1998-11-16 TN TNTNSN98206A patent/TNSN98206A1/fr unknown
- 1998-11-16 JP JP2000520798A patent/JP4550273B2/ja not_active Expired - Fee Related
- 1998-11-16 PL PL98340373A patent/PL340373A1/xx unknown
- 1998-11-16 TR TR2000/01384T patent/TR200001384T2/xx unknown
- 1998-11-16 AP APAP/P/2000/001825A patent/AP1196A/en active
- 1998-11-16 DZ DZ980264A patent/DZ2654A1/xx active
- 1998-11-16 GE GEAP19985410A patent/GEP20032968B/en unknown
- 1998-11-16 HU HU0004507A patent/HUP0004507A3/hu unknown
- 1998-11-16 KR KR1020007005317A patent/KR20010032130A/ko not_active Application Discontinuation
- 1998-11-16 MA MA25348A patent/MA26566A1/fr unknown
- 1998-11-16 ES ES98955662T patent/ES2224446T3/es not_active Expired - Lifetime
- 1998-11-16 BR BR9814199-6A patent/BR9814199A/pt not_active Application Discontinuation
- 1998-11-16 YU YU29600A patent/YU29600A/sh unknown
- 1998-11-16 EA EA200000531A patent/EA003322B1/ru not_active IP Right Cessation
- 1998-11-16 AU AU12425/99A patent/AU744419B2/en not_active Ceased
- 1998-11-16 NZ NZ504305A patent/NZ504305A/xx unknown
- 1998-11-16 EP EP98955662A patent/EP1030673B1/fr not_active Expired - Lifetime
- 1998-11-16 WO PCT/FR1998/002436 patent/WO1999025365A1/fr not_active Application Discontinuation
- 1998-11-16 CN CN98813159A patent/CN1286633A/zh active Pending
- 1998-11-16 CA CA002312021A patent/CA2312021C/fr not_active Expired - Fee Related
- 1998-11-16 SK SK704-2000A patent/SK7042000A3/sk unknown
- 1998-11-16 DE DE69825308T patent/DE69825308T2/de not_active Expired - Lifetime
- 1998-11-17 AR ARP980105823A patent/AR014119A1/es not_active Application Discontinuation
-
2000
- 2000-05-11 NO NO20002435A patent/NO20002435L/no unknown
- 2000-05-11 BG BG104427A patent/BG104427A/xx unknown
- 2000-05-17 OA OA1200000144A patent/OA11411A/fr unknown
- 2000-05-17 HR HR20000314A patent/HRP20000314A2/hr not_active Application Discontinuation
-
2007
- 2007-09-28 US US11/863,329 patent/US20080139489A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104470941B (zh) | 靶向治疗学 | |
| EP1496911B1 (en) | Use of a combination comprising a2a adenosine receptor agonists and anti-pathogenic agents for the treatment of inflammatory diseases | |
| US5643935A (en) | Method of combatting infectious diseases using dicationic bis-benzimidazoles | |
| US20080139489A1 (en) | Use of ketolides for preventing arterial thrombotic complications related to atherosclerosis | |
| ES2261523T3 (es) | Inhibidores de farnesil proteina transferasa para el tratamiento de enfermedad intestinal inflamatoria. | |
| WO2007120972A2 (en) | Method to treat sickle cell disease | |
| SK19872000A3 (sk) | Inhibítory farnezyl-proteín transferázy na liečbu artropatií | |
| KR20140107174A (ko) | 유방암의 치료 | |
| KR940001883A (ko) | 2-(n-(2-아미노에틸)아미노)아세트산 유도체의 용도 | |
| HRP20120478T1 (hr) | Formulacije koje sadrže spojeve srodne jorumicinu renieramicinu safracinu ili saframicinu i disaharid za liječenje proliferativnih oboljenja | |
| JP2006515866A5 (hr) | ||
| YU7302A (sh) | Heterociklična jedinjenja za inhibiranje angiogeneze | |
| PT99091B (pt) | Processo para a preparacao de composicoes farmaceuticas contendo derivados da triazina e da pirimidina, como ingredientes activos, destinadas a reverter a resistencia aos agentes anticancerosos e antimalaricos | |
| US5641753A (en) | 10-AZA-9-deoxo-11-deoxy-erythromycin A and derivatives combined with sulfisoxazole | |
| US20090176888A1 (en) | Composition comprising phytosphingosine or derivative thereof | |
| JPH08506353A (ja) | ウシもしくはブタの細菌感染における免疫刺激剤としてのｈ２−拮抗剤 | |
| CZ20001798A3 (cs) | Použití ketolidů pro přípravu farmaceutických prostředků určených pro předcházení arteriálním trombotickým komplikacím spojeným s atherosklerosou | |
| CN102603755B (zh) | 一类具有协同氟康唑抗耐药真菌作用的化合物 | |
| SK3912000A3 (en) | Tetrahydrofuran phosphate- and hydroxy esters, as prodrugs for the corresponding antifungal agent | |
| Öz | Investigation of cytotoxic effects of some novel synthesized iminothiazolidinone derivatives on HeLa cell line (CCL2) | |
| de Souza | Known Drugs Against Different Targets or Diseases Evaluated Against Tuberculosis | |
| JP2003530347A (ja) | クラミジア・ニューモニエ感染症の治療に有用な医薬組成物を製造するためのチアムフェニコール及びその誘導体の使用 | |
| FR2789078B3 (fr) | Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant | |
| WO2013027040A1 (en) | Cyclic oligosaccharides for use in the treatment and prevention of bacterial infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20021105 Year of fee payment: 5 |
|
| PNAN | Change of the applicant name, address/residence |
Owner name: AVENTIS PHARMA S.A., FR |
|
| ODBI | Application refused |